At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Selumetinib Sulfate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Selumetinib Sulfate for KRAS NP_004976.2:p.G12R and 2 related conditions. Completed, enrolled 8 participants across 9 sites.
Detailed Summary
This phase II trial studies how well selumetinib sulfate works in treating patients with pancreatic cancer with Kirsten rat sarcoma (KRAS) G12R mutations that has spread from where it started to nearby tissue or lymph nodes or other places in the body. Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKRAS NP_004976.2:p.G12R, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartJul 2017
Primary CompletionAug 2018
Study CompletionOct 2020
TodayJul 2026
First PostedFeb 2, 2017
Enrollment StartJul 21, 2017
Primary CompletionAug 10, 2018
Study CompletionOct 15, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.4 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Selumetinib Sulfatedrug
Given by mouth (PO)